Fabomotizole mesylate | anxiolytic

MedKoo Cat#: 573950 | Name: Fabomotizole mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fabomotizole, also known as Afobazole, is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.

Chemical Structure

Fabomotizole mesylate

CAS#Fabomotizole mesylate

Theoretical Analysis

MedKoo Cat#: 573950

Name: Fabomotizole mesylate

CAS#: Fabomotizole mesylate

Chemical Formula: C16H25N3O5S2

Exact Mass: 0.0000

Molecular Weight: 403.51

Elemental Analysis: C, 47.63; H, 6.25; N, 10.41; O, 19.82; S, 15.89

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 850.00	2 Weeks
250mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

173352-21-1 (free base) 173352-39-1 (HCl) 189638-30-0 (2HCl) Fabomotizole mesylate

Synonym

Obenoxazine; Afobazol; Afobazole; Aphobazole; CM-346; CM346; CM 346; Fabomotizole; Fabomotizole mesylate

IUPAC/Chemical Name

4-(2-((5-ethoxy-1H-benzo[d]imidazol-2-yl)thio)ethyl)morpholine mesylate

InChi Key

KOGSOYODMCMSTR-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H21N3O2S.CH4O3S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18;1-5(2,3)4/h3-4,11H,2,5-10H2,1H3,(H,16,17);1H3,(H,2,3,4)

SMILES Code

CCOC1=CC=C2NC(SCCN3CCOCC3)=NC2=C1.OS(=O)(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 403.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vakhitova YV, Kuzmina US, Voronin MV, Zainullina LF, Seredenin SB. Effect of Fabomotizole on Brain Gene Expression in MR Rats in the Open Field Test. Dokl Biochem Biophys. 2019 Sep;488(1):313-315. doi: 10.1134/S1607672919050090. Epub 2019 Nov 25. PMID: 31768849. 2: Tsorin IB, Barchukov VV, Vititnova MB, Kryzhanovskii SA, Seredenin SB. Anti- Ischemic Activity of Fabomotizole Hydrochloride under Conditions of Endothelial Dysfunction. Bull Exp Biol Med. 2019 Sep;167(5):634-636. doi: 10.1007/s10517-019-04586-x. Epub 2019 Nov 8. PMID: 31705224. 3: Kryzhanovskii SA, Tsorin IB, Stolyaruk VN, Vititnova MB, Ionova EO, Barchukov VV, Kozhevnikova LM, Seredenin SB. Examination of Cardioprotective Effects of Fabomotizole Hydrochloride in Translational Rat Model of Chronic Heart Failure. Bull Exp Biol Med. 2019 Nov;168(1):33-37. doi: 10.1007/s10517-019-04639-1. Epub 2019 Nov 18. PMID: 31741244. 4: Pérez-Villanueva J, Yépez-Mulia L, Rodríguez-Villar K, Cortés-Benítez F, Palacios-Espinosa JF, Soria-Arteche O. The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study. Eur J Med Chem. 2021 Feb 5;211:113110. doi: 10.1016/j.ejmech.2020.113110. Epub 2020 Dec 17. PMID: 33360795. 5: Kryzhanovskii SA, Kozhevnikova LM, Tsorin IB, Sukhanova IF, Ionova EO, Stolyaruk VN, Vititnova MB, Miroshkina IA, Seredenin SB. On the Mechanism of the Cardioprotective Action of σ1 Receptor Agonist Anxiolytic Fabomotizole Hydrochloride (Afobazole). Bull Exp Biol Med. 2018 Sep;165(5):660-664. doi: 10.1007/s10517-018-4236-1. Epub 2018 Sep 17. PMID: 30225699. 6: Pogosova NV, Yufereva YM, Ausheva AK, Kursakov AA, Arutyunov AA, Boytsov SA. [The Possibility of Correcting Anxiety Symptoms in Cardiac Patients in Primary Care Settings: Results of the Therapeutic Part of a Russian Multicenter Study COMETA]. Kardiologiia. 2019 Sep 17;59(9):29-39. Russian. doi: 10.18087/cardio.2019.9.n468. PMID: 31540574. 7: Kryzhanovskii SA, Antipova TA, Vititnova MB, Nikolaev SV, Durnev AD. Angiogenic Effects of Anxiolytic Fabomotizole. Dokl Biochem Biophys. 2021 Mar;497(1):63-65. doi: 10.1134/S1607672921020101. Epub 2021 Apr 24. PMID: 33895918. 8: Voronin MV, Vakhitova YV, Tsypysheva IP, Tsypyshev DO, Rybina IV, Kurbanov RD, Abramova EV, Seredenin SB. Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole. Int J Mol Sci. 2021 May 21;22(11):5455. doi: 10.3390/ijms22115455. PMID: 34064275. 9: Kolik LG, Nadorova AV, Stolyaruk VN, Miroshkina IA, Tsorin IB, Kryzhanovskii SA. Anxiolytic Properties of Trimetazidine in Experimental Models of Increased Anxiety. Bull Exp Biol Med. 2017 Mar;162(5):643-646. doi: 10.1007/s10517-017-3677-2. Epub 2017 Mar 31. PMID: 28361425. 10: Kryzhanovskii SA, Kozhevnikova LM, Vititnova MB, Efimova AO, Stolyaruk VN, Tsorin IB. On the Mechanism of Cardioprotective Effect of Fabomotizole in Alcoholic Cardiomyopathy. Bull Exp Biol Med. 2021 May;171(1):41-44. doi: 10.1007/s10517-021-05168-6. Epub 2021 May 29. PMID: 34050832. 11: Syunyakov TS, Neznamov GG. Otsenka terapevticheskoi effektivnosti i bezopasnosti selektivnogo anksiolitika afobazola pri generalizovannom trevozhnom rasstroistve i rasstroistvakh adaptatsii: rezul'taty mnogotsentrovogo randomizirovannogo sravnitel'nogo s diazepamom issledovaniya [Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: Results of a multicenter randomized comparative study of diazepam]. Ter Arkh. 2016;88(8):73-86. Russian. doi: 10.17116/terarkh201688873-86. PMID: 27636931.